Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

NCT02532218 is registered in ClinicalTrials.gov with Arisaph Pharmaceuticals Inc as lead sponsor.

NCT NCT02532218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02532218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
Lead sponsor
Arisaph Pharmaceuticals Inc
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2015
Completion date
December 31, 2016
Enrollment
176 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia